Literature DB >> 22392047

Inflammation-induced hepcidin is associated with the development of anemia and coronary artery lesions in Kawasaki disease.

Ho-Chang Kuo1, Ya-Ling Yang, Jiin-Haur Chuang, Mao-Meng Tiao, Hong-Ren Yu, Li-Tung Huang, Kuender D Yang, Wei-Chiao Chang, Chiu-Ping Lee, Ying-Hsien Huang.   

Abstract

PURPOSE: Kawasaki disease (KD) is a systemic febrile vasculitis complicated by coronary artery lesions (CAL). Anemia is common in patients with KD and is associated with a prolonged duration of active inflammation. Hepcidin is a central modulator of inflammation-associated anemia, acting via control of iron absorption and a direct inhibitory effect on erythropoiesis. The aims of this study were to investigate the role of inflammation-induced hepcidin in the development of anemia, the occurrence of CAL formation, and IVIG treatment response in patients with KD.
METHODS: Eighty-six KD patients and 30 febrile controls were enrolled. Levels of interleukin (IL)-6 and serum hepcidin were measured in sera by enzyme-linked immunosorbent assay. Hemoglobin and serum iron levels were also measured.
RESULTS: Hemoglobin and iron levels were lower in KD patients than in controls (p < 0.001 and p = 0.009, respectively). Serum hepcidin and IL-6 levels were higher in KD patients than in controls (both p < 0.001) before intravenous immunoglobulin (IVIG) treatment. After IVIG treatment, serum hepcidin, IL-6, and hemoglobin levels decreased significantly (all p < 0.001). In addition, the serum hepcidin levels before IVIG treatment were negatively correlated with hemoglobin levels after IVIG treatment (R = -0.188, p = 0.046) and positively correlated with the changes of hemoglobin levels after IVIG treatment (R = 0.269, p = 0.015). Furthermore, serum hepcidin levels were negatively correlated with serum iron levels (R = -0.412, p = 0.002), which were positively correlated with hemoglobin levels (R = 0.210, p = 0.045). Additionally, the change of hepcidin levels was associated with IVIG treatment response and the occurrence of CAL formation.
CONCLUSIONS: Inappropriately raised hepcidin levels impair iron metabolism and are associated with decreased hemoglobin levels in KD patients. Inflammation-induced hepcidin is associated with the development of anemia and disease outcomes in patients with KD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22392047     DOI: 10.1007/s10875-012-9668-1

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  35 in total

1.  Severe hemolytic anemia following high-dose intravenous immunoglobulin administration in a patient with Kawasaki disease.

Authors:  M Nakagawa; N Watanabe; M Okuno; M Kondo; H Okagawa; T Taga
Journal:  Am J Hematol       Date:  2000-03       Impact factor: 10.047

2.  Assessment of urinary concentrations of hepcidin provides novel insight into disturbances in iron homeostasis during malarial infection.

Authors:  Quirijn de Mast; Behzad Nadjm; Hugh Reyburn; Erwin H J M Kemna; Ben Amos; Coby M M Laarakkers; Simphorosa Silalye; Hans Verhoef; Robert W Sauerwein; Dorine W Swinkels; Andre J A M van der Ven
Journal:  J Infect Dis       Date:  2009-01-15       Impact factor: 5.226

Review 3.  Ferroportin1: a new iron export molecule?

Authors:  Nghia T V Le; Des R Richardson
Journal:  Int J Biochem Cell Biol       Date:  2002-02       Impact factor: 5.085

Review 4.  Diagnosis and management of anaemia of chronic disease: current status.

Authors:  Jonathan O Cullis
Journal:  Br J Haematol       Date:  2011-05-25       Impact factor: 6.998

5.  Assessment of risk factors for Korean children with Kawasaki disease.

Authors:  Jae-Jung Kim; Young Mi Hong; Sin Weon Yun; Myung Ki Han; Kyung-Yil Lee; Min Seob Song; Hyoung-Doo Lee; Dong Soo Kim; Sejung Sohn; Kee-Soo Ha; Soo-Jong Hong; Kwi-Joo Kim; In-Sook Park; Gi Young Jang; Jong-Keuk Lee
Journal:  Pediatr Cardiol       Date:  2011-11-22       Impact factor: 1.655

Review 6.  Kawasaki disease: infection, immunity and genetics.

Authors:  Chih-Lu Wang; Yu-Tsun Wu; Chieh-An Liu; Ho-Chang Kuo; Kuender D Yang
Journal:  Pediatr Infect Dis J       Date:  2005-11       Impact factor: 2.129

7.  Hepcidin in trauma: linking injury, inflammation, and anemia.

Authors:  Kristen C Sihler; Krishnan Raghavendran; Mark Westerman; Wen Ye; Lena M Napolitano
Journal:  J Trauma       Date:  2010-10

8.  Transient erythroblastopenia in a child with Kawasaki syndrome: a case report.

Authors:  G R Frank; I Cherrick; G Karayalcin; E Valderrama; P Lanzkowsky
Journal:  Am J Pediatr Hematol Oncol       Date:  1994-08

9.  The relationship of eosinophilia to intravenous immunoglobulin treatment failure in Kawasaki disease.

Authors:  Ho-Chang Kuo; Kuender D Yang; Chi-Di Liang; Chin-Nam Bong; Hong-Ren Yu; Lin Wang; Chih-Lu Wang
Journal:  Pediatr Allergy Immunol       Date:  2007-06       Impact factor: 6.377

10.  STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo.

Authors:  Antonello Pietrangelo; Uta Dierssen; Linda Valli; Cinzia Garuti; Agrani Rump; Elena Corradini; Matthias Ernst; Christian Klein; Christian Trautwein
Journal:  Gastroenterology       Date:  2006-10-17       Impact factor: 22.682

View more
  22 in total

1.  Changes in Hemoglobin Concentrations Post-immunoglobulin Therapy in Patients with Kawasaki Disease: A Population-Based Study Using a Claims Database in Japan.

Authors:  Masato Takeuchi; Shuichi Ito; Masaki Nakamura; Koji Kawakami
Journal:  Paediatr Drugs       Date:  2018-12       Impact factor: 3.022

Review 2.  Balance of cardiac and systemic hepcidin and its role in heart physiology and pathology.

Authors:  Driton Vela
Journal:  Lab Invest       Date:  2017-10-23       Impact factor: 5.662

3.  Hepcidin in Kawasaki disease: upregulation by acute inflammation in patients having resistance to intravenous immunoglobulin therapy.

Authors:  Takashi Ishikawa; Yasuyuki Wada; Hiroyuki Namba; Toshinao Kawai
Journal:  Clin Rheumatol       Date:  2021-06-19       Impact factor: 2.980

4.  High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.

Authors:  Ho-Chang Kuo; Mao-Hung Lo; Kai-Sheng Hsieh; Mindy Ming-Huey Guo; Ying-Hsien Huang
Journal:  PLoS One       Date:  2015-12-10       Impact factor: 3.240

5.  Genome-Wide Association Study Identifies Novel Susceptibility Genes Associated with Coronary Artery Aneurysm Formation in Kawasaki Disease.

Authors:  Ho-Chang Kuo; Sung-Chou Li; Mindy Ming-Huey Guo; Ying-Hsien Huang; Hong-Ren Yu; Fu-Chen Huang; Fuyong Jiao; Hsing-Chun Kuo; Jorge Andrade; Wen-Ching Chan
Journal:  PLoS One       Date:  2016-05-12       Impact factor: 3.240

6.  Associations of plasma hepcidin with mortality risk in patients with coronary artery disease.

Authors:  Xinrui Li; Ding Ding; Yuan Zhang; Dongfang Su; Min Wang; Xuechen Chen; Yan Yang; Changjiang Hong; Gang Hu; Wenhua Ling
Journal:  Oncotarget       Date:  2017-11-27

7.  Inverse correlation between serum interleukin-6 and iron levels among Japanese adults: a cross-sectional study.

Authors:  Hiroko Nakagawa; Takashi Tamura; Yoko Mitsuda; Yasuyuki Goto; Yoshikazu Kamiya; Takaaki Kondo; Kenji Wakai; Nobuyuki Hamajima
Journal:  BMC Hematol       Date:  2014-02-28

Review 8.  Can Coronary Artery Involvement in Kawasaki Disease be Predicted?

Authors:  Sunil J Ghelani; Neha S Kwatra; Christopher F Spurney
Journal:  Diagnostics (Basel)       Date:  2013-03-26

9.  Plasma Prostaglandin E2 Levels Correlated with the Prevention of Intravenous Immunoglobulin Resistance and Coronary Artery Lesions Formation via CD40L in Kawasaki Disease.

Authors:  Ho-Chang Kuo; Chih-Lu Wang; Kuender D Yang; Mao-Hung Lo; Kai-Sheng Hsieh; Sung-Chou Li; Ying-Hsien Huang
Journal:  PLoS One       Date:  2016-08-15       Impact factor: 3.240

10.  Hepcidin-Induced Iron Deficiency Is Related to Transient Anemia and Hypoferremia in Kawasaki Disease Patients.

Authors:  Ying-Hsien Huang; Ho-Chang Kuo; Fu-Chen Huang; Hong-Ren Yu; Kai-Sheng Hsieh; Ya-Ling Yang; Jiunn-Ming Sheen; Sung-Chou Li; Hsing-Chun Kuo
Journal:  Int J Mol Sci       Date:  2016-05-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.